SSH aims to raise $4.3m for Bio-Layer
Friday, 16 September, 2005
Sydney-based SSH Medical (ASX:SSH) has started accepting applications for subscriptions to raise approximately $4.3 million to provide working capital for material science company Bio-Layer, which SSH is acquiring.
Bio-Layer is developing biological surface-coating technology, with an initial focus on immunoassays and diagnostic tests.
SSH is currently receiving negligible commercial returns from its VedaScope business and will divest its MediStation operations as part of the overall transaction.
SSH will issue 15.2 million shares at AUD$0.28 and 7.6 million listed, tradable options will also be issued, free of charge, on a one for two basis. The prospectus was released on September 8.
The offer is being sponsored by EG Capital and is being made to SSH's existing 2,300 shareholders, clients of EG Capital and selected brokers. Prior to the capital raising, SSH anticipates undertaking a 10 for 1 share consolidation.
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
